What is he best known for?
The fields of study he is best known for:
- World War II
- Internal medicine
- Cancer
His scientific interests lie mostly in Internal medicine, Leukemia, Myeloid leukemia, Oncology and Surgery.
His Internal medicine study incorporates themes from Gastroenterology and Immunology.
The concepts of his Leukemia study are interwoven with issues in Myeloid, Chemotherapy and Pharmacology.
His Myeloid leukemia study introduces a deeper knowledge of Cancer research.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Hematopoietic stem cell transplantation, Adverse effect, Myelodysplastic syndromes and Hazard ratio.
His work investigates the relationship between Surgery and topics such as Bone marrow that intersect with problems in Lymphoma, Complication and Lenalidomide.
His most cited work include:
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (2837 citations)
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B (1474 citations)
- A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome (1452 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Myeloid leukemia, Oncology, Leukemia and Cancer research.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Immunology.
His Oncology study combines topics in areas such as Clinical trial, Myelodysplastic syndromes and Transplantation.
His Leukemia study combines topics from a wide range of disciplines, such as Myeloid, Cancer, Haematopoiesis and Bone marrow.
The various areas that he examines in his Cancer research study include Tyrosine kinase and Mutant.
His Cytarabine research integrates issues from Daunorubicin and Induction chemotherapy.
He most often published in these fields:
- Internal medicine (25.56%)
- Myeloid leukemia (17.41%)
- Oncology (14.51%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (25.56%)
- Myeloid leukemia (17.41%)
- Oncology (14.51%)
In recent papers he was focusing on the following fields of study:
Richard Stone mainly focuses on Internal medicine, Myeloid leukemia, Oncology, Cancer research and Leukemia.
His study in Cytarabine, Transplantation, Chemotherapy, Clinical trial and Chemotherapy regimen falls under the purview of Internal medicine.
His Myeloid leukemia research focuses on Adverse effect and how it connects with Febrile neutropenia.
His study in Oncology is interdisciplinary in nature, drawing from both European LeukemiaNet, Hematopoietic stem cell transplantation, NPM1 and Midostaurin.
His research integrates issues of Haematopoiesis, Mutant and Kinase in his study of Cancer research.
His Leukemia research is multidisciplinary, relying on both Myeloid and Cancer.
Between 2014 and 2021, his most popular works were:
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (802 citations)
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia (640 citations)
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts (556 citations)
In his most recent research, the most cited papers focused on:
- World War II
- Internal medicine
- Cancer
His primary scientific interests are in Internal medicine, Myeloid leukemia, Leukemia, Oncology and Myeloid.
Cytarabine, Clinical trial, Transplantation, Adverse effect and Chemotherapy are subfields of Internal medicine in which his conducts study.
His Myeloid leukemia study integrates concerns from other disciplines, such as Gastroenterology, Enasidenib and NPM1.
His Leukemia study is related to the wider topic of Immunology.
His Oncology research includes themes of Ibrutinib, Surgery, Refractory and Rituximab.
His Myeloid research is multidisciplinary, relying on both Survival rate, Bone marrow and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
